Document:

Exhibit 10.1

Exhibit 10.1

Amendment No. 3 to Agreement for Marketing Services

This Amendment No. 3 dated as of August 16, 2010 (this “Amendment”) is to the Agreement for Marketing Services
dated January 14, 2008, as amended April 30, 2009 and May 15, 2009 (the “Agreement”) by and between ALPS Distributors,
Inc., a Colorado corporation located at 1290 Broadway, Suite 1100, Denver, Colorado 80203 (“ALPS”), and GreenHaven
Commodity Services, LLC, a Delaware limited liability company located at 3340 Peachtree Road, Suite 1910, Atlanta,
Georgia 30326 (the “Client”).

WHEREAS, ALPS and the Client wish to amend the Agreement in certain respects as more fully set forth below
effective as of the date of this Amendment; and

NOW, THEREFORE, in consideration of the mutual covenants herein contained and for good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows:

1. The first “WHEREAS” clause of the Agreement is replaced in its entirety with the following:

WHEREAS, the Client is the managing owner of GreenHaven Continuous Commodity Index
Fund, a Delaware statutory trust that is listed on the New York Stock Exchange ARCA (the
“Feeder Fund”) and of GreenHaven Continuous Commodity Index Master Fund, a Delaware
statutory trust and a commodity index-linked fund in which the Feeder Fund has invested all
of its assets (the “Master Fund,” collectively with the Feeder Fund, the
“Funds”); and

2. Section 2 (Fees) of the Agreement is replaced in its entirety as follows:

2. Fees. For the performance by ALPS of the Services pursuant to this Agreement,
Client agrees to pay ALPS an annual fee, amortized monthly and payable quarterly, based
upon the Feeder Fund’s net assets, in accordance with the fee schedule set forth on
Exhibit B hereto.

3. Exhibit B (Fees) is replaced in its entirety with the new Exhibit B (Fees) attached hereto and incorporated by
referenced herein.

4. Section 3 (Out of Pocket Expenses) of the Agreement is replaced in its entirety as follows:

3. Out of Pocket Expenses. In addition to the fees that the Client shall pay to
ALPS pursuant to Section 2 above, the Client agrees to reimburse ALPS for its reasonable
out-of-pocket expenses incurred and advances made by ALPS in performing the Services,
including, but specifically not limited to, FINRA advertising fees, registered
representative licensing fees, branch inspection costs, postage and any other expenses
incurred by ALPS at the specific written request or consent of the Client, up to a total of
$177,000 for the two-year period beginning October 21, 2009.

 

1

 

5. Section 14 (Assignment) and Section 15 (Change in Control of the Client) are added to and incorporated by
reference in the Agreement as follows:

14. Assignment. This Agreement shall extend to and shall be binding upon the parties hereto
and their respective successors and permitted assigns; provided, however, that this Agreement shall
not be assignable by the Client without the prior written consent of ALPS, or by ALPS without the
prior written consent of the Client.

15. Change in Control of the Client. In the event (i) there is a Change in Control (as
defined below) of the Client and ALPS is not subsequently retained to provide the Services under this
Agreement by the Client’s successor(s) or (ii) the Client terminates this Agreement without cause
(“Termination Without Cause”), the Client agrees to pay to ALPS a cash payment equal to:
(i) eighteen (18) times the most recent monthly Fee (excluding any waivers in effect) payable to ALPS
under this Agreement, in addition to all outstanding Fees under this Agreement (together with the
Fees, the “Aggregate Fees”)) for a Change in Control of the Client or Termination Without
Cause that occurs within three (3) years of October 21, 2009 or (ii) twelve (12) times the aggregate
of all Aggregate Fees for a Change in Control of the Client or Termination Without Cause that occurs
between on October 21, 2012 through October 21, 2014. For purposes of this Agreement, a “Change
in Control” is defined as (i) the consummation of a reorganization, merger, consolidation or sale
or disposition of all or substantially all of the assets of the Client or (ii) any transaction which
results in the ownership interests in GreenHaven, LLC of Thomas J. Fernandes and Ashmead Pringle
falling below 51% when combined.

6. Except as specifically set forth herein, all other provisions of the Agreement shall remain in full force and
effect. Any items not herein defined shall have the meaning ascribed to them in the Agreement.

[The remainder of this page left intentionally blank.]

 

2

 

IN WITNESS WHEREOF, the parties hereto have duly executed and delivered this Amendment as of the date first
written above.

	 	 	 
	GREENHAVEN COMMODITY SERVICES, LLC	 	ALPS DISTRIBUTORS, INC.
	 	 	 
	By: /s/ Ashmead F. Pringle, III                                    

	 	By: /s/ Thomas A. Carter              
	Name: Ashmead F. Pringle, III

	 	Name: Thomas A. Carter
	Title: Manager

	 	Title: President

 

3

 

EXHIBIT B

Fees

The annual fees payable to ALPS for the Services under this Agreement are as follows:

	 	 	 
	Feeder Fund Assets	 	ALPS Fees as a % of Feeder Fund Net Assets
	1. $0 – below $300 million
	 	0.05%*
	2. $300 million – $1 billion
	 	0.15% on all Feeder Fund net assets up to $1 billion
	3. Over $1 billion – $2.5 billion
	 	0.125%
	4. Over $2.5 billion
	 	0.10%

* Notwithstanding anything in the Agreement to the contrary, the annual fees of 0.05% on all Feeder Fund net assets in
line 1 above shall be increased to 0.15% on all Feeder Fund net assets as of the earlier of (i) July 1, 2010 and
(ii) the date on which Feeder Fund net assets reach $300 million. All net asset values will be per the Bank of New
York or its successor as the Client’s fund administrator.

 

4exv10w1

Exhibit
10.1

CONFIDENTIAL

	 	*	 	Confidential Treatment has
been requested for the
marked portions of this
exhibit pursuant to Rule
24B-2 of the Securities
Exchange Act of 1934, as
amended.

WYETH LLC

ACTING THROUGH ITS

WYETH PHARMACEUTICALS DIVISION

500 Arcola Road

Collegeville, Pennsylvania 19426 USA

April 12, 2010

Trubion Pharmaceuticals, Inc.

2401 4th Avenue, Suite 1050

Seattle, Washington 98121

Re: Amendment No. 2 to the Collaboration and License Agreement dated as of December 19,
2005 (as previously amended, the “Agreement”) by and between Trubion
Pharmaceuticals, Inc. (“Trubion”) and Wyeth LLC (formerly known as Wyeth), acting through
its Wyeth Pharmaceuticals Division (“Wyeth”)

Ladies and Gentlemen:

This letter agreement (the “Letter Agreement”) constitutes Amendment No. 2 to the Agreement
referred to above. Capitalized terms used but not defined herein shall have the meanings set forth
in the Agreement. Trubion and Wyeth desire to discontinue their collaborative efforts toward the
research and Development of [*] and, as a result thereof, wish to amend the Agreement as set forth
herein. In addition, Trubion and Wyeth desire to discontinue their collaborative efforts towards
the research and Development of the following Wyeth Targets: [*] (the “Discontinued Targets”), of SMIPs directed against such Discontinued Targets (the
“Discontinued SMIPs”) and of Other Products containing SMIPS directed against such Discontinued
Targets (the “Discontinued Other Products”). This Letter Agreement sets forth the agreement of
Trubion and Wyeth with respect to such amendment.

Each of Trubion and Wyeth agrees that, upon execution of this Letter Agreement, (a) all rights and
licenses granted to Wyeth by Trubion under the Agreement with respect to [*] shall immediately
terminate, and Wyeth shall have no further obligations to Trubion under the

*Confidential
Treatment Requested.

 

 

			
	Trubion Pharmaceuticals, Inc.
	 	CONFIDENTIAL
	April 12, 2010	 	 
	Page 2 of 4	 	 

Agreement with respect to [*], (b) all rights and licenses granted to Wyeth by Trubion under the
Agreement with respect to the Discontinued Targets, the Discontinued SMIPs or the Discontinued
Other Products shall immediately terminate, and Wyeth shall have no further obligations to Trubion
under the Agreement with respect to the Discontinued Targets, the Discontinued SMIPs or the
Discontinued Other Products, (c) Trubion shall have no further obligations to Wyeth under the
Agreement with respect to [*], the Discontinued Targets, the Discontinued SMIPs or the Discontinued
Other Products, and (d) the Discontinued Targets shall be deemed Released Targets for purposes of
Section 3.2.2 of the Agreement. Notwithstanding the foregoing or any provision in the Agreement to
the contrary but subject to the following sentence, each of Trubion and Wyeth agrees that the
Research Program shall continue in full force and effect in accordance with the terms of the
Agreement with respect to Licensed Targets other than [*] and the Discontinued Targets and with
respect to Products other than [*] and the Discontinued Other Products. Wyeth and Trubion agree
that the Research Term hereby is extended until December 31, 2010. The following Targets remain
Wyeth Targets under the Agreement: [*] (the “Remaining Wyeth Targets”).

In connection with the foregoing, each of Trubion and Wyeth agree to make the following amendments
to the Agreement:

	1.	 	Amendments to Article 1. Article 1 of the Agreement hereby is amended by

	 	a.	 	deleting Sections 1.46 through 1.49 of Article 1 in their entirety;
	 
	 	b.	 	in Section 1.93, deleting the phrase [*] each time it appears within
the definition of “Product”;
	 
	 	c.	 	replacing Section 1.130 in its entirety with “‘Trubion Target’ shall
mean the human CD20 Antigen”; and
	 
	 	d.	 	replacing Section 1.140 in its entirety with “‘Wyeth Targets’ shall mean the Targets designated
by Wyeth under the Research Program, as described in Section 3.2 hereof. Notwithstanding anything
herein to the contrary, as of April 12, 2010 the Wyeth Targets are [*] (all of which have been
previously designated as Wyeth Targets pursuant to Section 3.2 hereof); any other Targets previously designated by Wyeth as Wyeth Targets pursuant to
Section 3.2 are no longer Wyeth Targets for purposes of the Agreement.”

	2.	 	Amendments to Article 2. Article 2 of the Agreement is hereby amended by

	 	a.	 	deleting Section 2.3.2 in its entirety; and
	 
	 	b.	 	in Section 2.3.3 replacing the phrase “Sections 2.3.1 and 2.3.2” with
“Section 2.3.1”.

	3.	 	Amendments to Article 3. Article 3 of the Agreement is hereby amended by

	 	a.	 	in Section 3.1 deleting the phrase [*] from clause (a) thereof.

	4.	 	Amendments to Article 4. Article 4 of the Agreement is hereby amended by

	 	a.	 	in Section 4.5(a), deleting the phrase [*]; and
	 
	 	b.	 	deleting Section 4.5(c) in its entirety.

*Confidential
Treatment Requested.

 

 

			
	Trubion Pharmaceuticals, Inc.
	 	CONFIDENTIAL
	April 12, 2010	 	 
	Page 3 of 4	 	 

	5.	 	Amendments to Article 5. Article 5 of the Agreement is hereby amended by

	 	a.	 	deleting the reference to Section 5.4.3 from Section 5.4.1.
	 
	 	b.	 	deleting Section 5.4.3 in its entirety;
	 
	 	c.	 	deleting the second sentence of Section 5.4.6(a) in its entirety;
	 
	 	d.	 	deleting the last sentence of Section 5.5.1 in its entirety; and
	 
	 	e.	 	replacing clause (c) of Section 5.5.2 in its entirety with “(c) any
adjustments (including the basis therefor) made pursuant to Sections 5.4.2(b),
5.4.2(c), 5.4.4(b), 5.4.4(c) or 5.4.6(a) to the royalty amount payable fore the
sale of each Licensed Product, the applicable Marginal Royalty Rates and the CD20
Effective Royalty Rate (as the case may be) payable on Net Sales, and”.

	6.	 	Amendments to Article 9. Article 9 of the Agreement is hereby amended by

	 	a.	 	in the second sentence of Section 9.7.2(a)(ii), deleting the phrase [*]
from each of clauses (B) and (C);
	 
	 	b.	 	in Section 9.8.4(i), deleting the phrase “or 2.3.2”;
	 
	 	c.	 	in Section 9.10.2(c), replacing the phrase “the restrictive covenants
set forth in Sections 2.3.1 and 2.3.2” with “the restrictive covenants set forth in
Section 2.3.1”, and deleting the phrase [*] each time it appears therein; and
	 
	 	d.	 	also in Section 9.10.2(c), deleting from the third sentence thereof the phrase “and/or all [*]
(only where such Existing Activities relate to products directed against the [*] which would otherwise violate
Wyeth’s exclusivity covenants in Section 2.3.2 hereof)”.

	7.	 	Amendments to Exhibit 5.3. Exhibit 5.3 of the Agreement is hereby amended by

	 	a.	 	Deleting Part B of Exhibit 5.3 in its entirety.
	 
	 	b.	 	In subclauses (i) and (iv) of Part D of Exhibit 5.3, replacing
“Sections A-C” with “Sections A and C”.
	 
	 	c.	 	In subclause (iv) of Part D of Exhibit 5.3, replacing, in the second
sentence thereof, [*] with “the human CD20 Antigen”.
	 
	 	d.	 	In subclause (v) of Part D of Exhibit 5.3, deleting, from the first
sentence thereof, the reference to Section B, and replacing, in second sentence
thereof, [*] with “CD20 Product” each time it appears therein.

This Amendment No. 2 shall become effective as of the date of this letter set forth above. As
modified by this Amendment No. 2, the Parties confirm that the Agreement is in full force and
effect.

*Confidential
Treatment Requested.

 

 

			
	Trubion Pharmaceuticals, Inc.
	 	CONFIDENTIAL
	April 12, 2010	 	 
	Page 4 of 4	 	 

Please indicate your acknowledgement of and agreement with the foregoing by having each counterpart
of this Letter Agreement executed on behalf of Trubion and returning one fully executed original
counterpart to me.

	 	 	 	 	 
	Very truly yours,

WYETH LLC, acting through its

WYETH PHARMACEUTICALS DIVISION

 	 
	By:  	/s/ ROBERT J. SMITH
 	 
	 	Name:  	Robert J. Smith 	 
	 	Title:  	Senior Vice President 	 
	 
	ACKNOWLEDGED AND AGREED:

TRUBION PHARMACEUTICALS, INC.

 	 
	By:  	/S/ MICHELLE G. BURRIS
 	 
	 	Name:  	Michelle G. Burris 	 
	 	Title:  	SVP, COO

 	 
	Date: 14 April 2010

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00177-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00177-of-00352.parquet"}]]